

# **2024 World Breast Cancer Diagnostics Market--CEA, CA 15-3, CA 27.29,CA 125, Estrogen Receptor, HER2, Polypeptide-Specific Antigen, Progesterone Receptor-- A 92-Country Database and Analysis, 2023 Supplier Shares and Strategies, 2023-2028 Volume and Sales Segment Forecasts, Emerging Technologies, Latest Instrumentation, Growth Opportunities**

<https://marketpublishers.com/r/24CB84F4DE9FEN.html>

Date: January 2024

Pages: 0

Price: US\$ 9,500.00 (Single User License)

ID: 24CB84F4DE9FEN

## **Abstracts**

This new 92-country report from LeadingMarketResearch.com is available by region, country, market segment, section, individual marker, and can be customized to specific information needs and budget.

This report is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding breast cancer diagnostic testing market, in evaluating emerging opportunities and developing effective business strategies during the next five years.

The report provides granular market segmentation analysis and forecasts for major breast cancer markers; profiles leading suppliers and recent market entrants with innovative technologies and products; reviews current assays and instrumentation; evaluates emerging technologies; and offers specific opportunities and growth strategies for suppliers.

Rationale

The breast cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide breast cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.

## Geographic Regions and Countries

### Asia-Pacific

Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Myanmar, New Zealand, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand, Turkey, Vietnam

### Europe

Albania, Austria, Belarus, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Georgia, Germany, Greece, Hungary, Iceland, Ireland, Italy, Kazakhstan, Latvia, Lithuania, Malta, Moldova, Netherlands, Norway, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, UK, Ukraine

### Latin America

Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Cuba, Dominican Republic, Ecuador, El Salvador, Guatemala, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Paraguay, Peru, Puerto Rico, Uruguay, Venezuela

### Middle East

Bahrain, Iran, Iraq, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, United Arab Emirates

### North America

Canada, Mexico, USA

### Business Opportunities and Strategic Recommendations

Specific new product development opportunities with potentially significant market appeal during the next five years

Design criteria for new products

Alternative market penetration strategies

Potential market entry barriers and risks

### Supplier Shares, Sales and Volume Forecasts

Sales and market shares of major suppliers

Five-year test volume and sales forecasts by assays

### Instrumentation Review

Analysis of major analyzers used for breast cancer testing

### Technology Assessment

Assessment of latest technologies and their potential applications for breast cancer diagnostic testing

Review of competing/complementing technologies

Companies, universities and research centers developing new breast cancer diagnostic tests and detection technologies

### Competitive Strategies

Strategic assessments of major suppliers and start-up firms developing innovative breast cancer diagnostic technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.

The companies analyzed in the report include:

Abbott, Affymetrix, Beckman Coulter/Danaher, Becton Dickinson, bioMerieux, Bio-Rad, DiaSorin, Eiken Chemical, Elitech Group, Enzo Biochem, Fujirebio, Fujifilm Wako, Grifols, Hologic, Leica Biosystems, PerkinElmer, Qiagen, QuidelOrtho, Roche, Siemens Healthineers, Takara Bio, Thermo Fisher, and others.

## Contents

- I. Introduction
- II. Worldwide Market Overview
- III. Major Product Development Opportunities
  - A. Reagent Kits and Test Systems/Panels
  - B. Instrumentation
  - C. Computers, Software and Automation
  - D. Auxiliary Products
- IV. Design Criteria for Decentralized Testing Products
- V. Alternative Market Penetration Strategies
  - A. Internal Development
  - B. Collaborative Arrangements
  - C. University Contracts
  - D. Distribution Strategies
- VI. Potential Market Entry Barriers and Risks
  - A. Market Maturity
  - B. Cost Containment
  - C. Competition
  - D. Technological Edge and Limitations
  - E. Patent Protection
  - F. Regulatory Constraints
  - G. Decentralized Testing Market Challenges
- VII. Worldwide Market and Technology Overview
  - A. Cancer Statistics and Etiology

### **1. BREAST CANCER**

### **2. LUNG CANCER**

### **3. COLON AND RECTUM CANCER**

### **4. PROSTATE CANCER**

### **5. STOMACH CANCER**

## **6. LEUKEMIA**

## **7. LYMPHOMA**

## **8. ORAL CANCER**

## **9. SKIN CANCER**

## **10. UTERINE CANCER**

## **11. OVARIAN CANCER**

## **12. BLADDER CANCER**

## **B. Major Current and Emerging Cancer Diagnostic Tests**

### **1. INTRODUCTION**

### **2. TUMOR MARKER CLASSIFICATION**

### **3. ACTH**

### **4. ALPHA-FETOPROTEIN (AFP)**

### **5. BETA-2 MICROGLOBULIN**

**6. CA 15-3/27.29**

**7. CA 19-9**

**8. CA-125**

**9. CALCITONIN**

**10. CARCINOEMBRIONIC ANTIGEN (CEA)**

**11. ESTROGEN AND PROGESTERONE RECEPTORS**

**12. FERRITIN**

**13. GASTRIN**

**14. HUMAN CHORIONIC GONADOTROPIN (HCG)**

**15. INSULIN**

**16. NSE**

**17. OCCULT BLOOD**

**18. PAP SMEAR/HPV**

**19. PROSTATIC ACID PHOSPHATASE (PAP)****20. PROSTATE-SPECIFIC ANTIGEN (PSA)****21. SQUAMOUS CELL CARCINOMA ANTIGEN (SCC)****22. T AND B LYMPHOCYTES****23. TDT****24. THYROGLOBULIN****25. TISSUE POLYPEPTIDE ANTIGEN (TPA)****26. BIOCHEMICAL TUMOR MARKERS****27. ONCOGENES**

- Abl/abl-bcr
- AIB1
- BCL-2
- BRCA1
- CD44
- C-fos
- C-myb
- C-myc
- CYP-17
- Erb-B
- HPC1
- N-myc
- P40



- P51
- P53
- PIK3CA
- PTI-1
- Ras
- Reg
- Sis
- Src and others

## **28. POLYPEPTIDE GROWTH FACTORS**

- Basic Fibroblast Growth Factor
- Beta-TGF
- Cachectin (TNT)
- Calmodulin
- ECFR
- Nerve Growth Factor (NGF)
- Epidermal Growth Factor (EGF)
- Ornithine Decarboxylase
- Transferrin
- Transforming Growth Factor-Alpha

## **29. ECTOPIC HORMONES**

## **30. COLONY STIMULATING FACTORS**

## **31. LYMPHOKINES**

- Alpha-Interferon
- B Cell Growth Factors
- B Cell Growth Factor (BCGF)
- Gamma-Interferon
- Interleukin-1 (IL-1)
- Macrophage Activating Factor

## **32. IMMUNOHISTOCHEMICAL STAINS**

### 33. EMERGING TUMOR MARKERS

- N-Acetylglucosamine
- Actin
- Alpha-Actin
- Antineuronal Antibodies
- 7B2
- B72.3
- Bax
- BCD-F9
- BLCA-4
- Blood Group Antigens A,B,H
- CA
- CA 72-4/TAG-72
- CA
- CA-242
- CA-549
- CAM
- CAR-3
- Cathepsin-D
- Chromogranin A and B
- Cluster 1 Antigen
- Cluster-5/5A Antigen
- CTA
- CU18
- DR-70
- DU-PAN-2
- Endometrial Bleeding Associated Factor
- Endostatin
- Epithelial Membrane Antigen
- Feulgen Hydrolysis
- Fibronectin
- FSH
- (1->3)-L-fucosyltransferase
- Gastrin-Releasing Peptide (GRP)
- GDCFP-15
- Glucagon
- Glycoamines

- H23
- Her-2
- Human Carcinoma Antigen
- HPA
- HSP27
- Intermediate Filaments
- Cytokeratins/CK18/Cyfra 21-1
- Desmin
- Gliofibrillary Acid Protein
- Neurofilaments
- Vimentin
- KA
- Kinases
- KP16D3
- LAI
- Leukocyte Common Antigen
- Lewis Antigens
- Lysophosphatidic Acid (LPA)
- Ma 695/Ma
- MABDF3
- MAG
- ME1
- Minactivin
- MN/CA9
- MSA
- Mucin Cancer Antigen (MCA)
- Multiple Tumor Suppressor
- Myosin
- NEA-130
- NMP22
- OA-519
- Opioid Peptides
- P-glycoprotein
- Pancreatic Oncofetal Antigen (POA)
- Placental Lactogen
- PR92

## I would like to order

Product name: 2024 World Breast Cancer Diagnostics Market--CEA, CA 15-3, CA 27.29,CA 125, Estrogen Receptor, HER2, Polypeptide-Specific Antigen, Progesterone Receptor-- A 92-Country Database and Analysis, 2023 Supplier Shares and Strategies, 2023-2028 Volume and Sales Segment Forecasts, Emerging Technologies, Latest Instrumentation, Growth Opportunities

Product link: <https://marketpublishers.com/r/24CB84F4DE9FEN.html>

Price: US\$ 9,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/24CB84F4DE9FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below  
and fax the completed form to +44 20 7900 3970